We work with Independent Pathology Businesses to Prepare for the Fast Moving Evolution in AI Technology
GPath Capital Partners invests in and partners with independent pathology lab owners who have built a successful, profitable business.
A Changing Technology Landscape
GPath brings capital, technology infrastructure, and operational support that can help your lab achieve more than it could alone, while offering immediate liquidity and the opportunity to participate in long-term value creation through public company equity.
THE TEAM
The Team Behind the Platform.
Experienced operators and investors who have done this before.
Our team brings decades of experience building and scaling healthcare companies in the public markets.
INVESTMENT THESIS
The future of independent pathology is at an inflection point.
Pathology is Evolving Faster Than Ever
Many Independent labs navigate the same challenges: rapid technological change, rising operating costs, and increasing competition from larger labs that are difficult and expensive to overcome without a capital partner.
Future success likely depends on finding a capital partner with a proven platform.
GPath Capital Partners is that platform.
A Platform Built Around Pathology that gives you:
Control over your pathology lab
Funds for technology upgrades
Guidance on technology implementation
All while giving you the opportunity to take cash off the table at closing so you can diversify your portfolio in an uncertain market.
Our investment criteria.
We invest in profitable, independent pathology labs with strong fundamentals and distinct capabilities and bring them into a growing public company platform designed to improve performance and provide liquidity at the highest possible price.
We provide access to resources.
We offer capital, technology, shared infrastructure and, where needed, operational support to help each lab grow and perform at a high level.
And everyone benefits.
Our investment thesis is simple:
Given the right support, great labs can deliver better outcomes and build lasting enterprise value to all stakeholders.
THE GPATH ADVANTAGE
We look for labs that were built for success and remove the constraints that hold them back.
We engage pathology labs with something special — a reputation in their market, a loyal client base, specialized capabilities, a team that has built real expertise over time, and positive cash flow.
Our model removes the natural constraints that come with building independently in an age of rapid technological change.
We provide:
Cash & Liquidity
Our goal is to provide what is missing.
And when exceptional labs join a coordinated platform the whole becomes greater than the sum of its parts.
Cross-selling and referral network expansion
Technology implementation support
Volume distribution and capacity utilization
Shared operating knowledge
HOW WE INVEST
We Take a Novel Approach to Pathology Investment
OUR MODEL
We invest through an earn-out structure that includes cash down and equity – the split depends upon your appetite for upside
We swap our liquid public stock for your illiquid private stock through a tax efficient structure
As the platform expands through additional acquisitions, shareholder’s value compounds.
The Benefits of Our Model
Liquidity today with future upside through a structure that may include both cash and public company shares
Additional value creation through stronger technology, infrastructure, and operating support
Continued control of the way your business operates
Access to broader revenue opportunities including additional capabilities and new revenue paths over time